ABT 378/r: a novel inhibitor of HIV-1 protease in haemodialysis
Hassane Izzedinea, Vincent
Launay-Vachera, Mayeule Legrandb,
Deborah Lieberherra, Eric Caumesc, and Gilbert Deraya
AIDS, 2001:15:662-665
| This paper is the first
pharmacokinetics report on the use of lopinavir/ritonavir in a patient
with renal failure. The patient was a 53-year-old HIV-infected man with a
history of systemic leishmaniasis that had been treated with
amphotericin B for 5 years and who developed chronic renal insufficiency.
The patient’s ARV regimen was stavudine, didanosine, lamivudine,
nevirapine, efavirenz, and lopinavir/ritonavir. No clinical or biological
adverse events were noted. The
pharmacokinetics study was conducted after the oral administration of a
three soft capsule dose of lopinavir/ritonavir between and during
dialysis sessions and the data are summarized in Table 1 in the paper.
According to the authors, the data suggest that that lopinavir/ritonavir
should be administered at normal dosages |
|
Departments of a Nephrology,
Pharmacology, and Infectious Diseases, Pitié Salpétriére Hospital, 47 – 83 Boulevard de l’Hôpital, 75013 Paris, France Abstract by Gordon Nary |
| KLS Journal Citations | KLS New and Noteworthy | Home Page |
|
ABT 378/r: a novel
inhibitor of HIV-1 protease in haemodialysis |